# Samphire Neuroscience

> Wearable neurotechnology focused on women's menstrual health.

## Why it is interesting

Samphire brings medical-device development to an underserved health category. Its commercial progress depends on clinical evidence, regulatory permissions, patient access and distribution, alongside the practical usability of the wearable.

## Profile

- **Latest funding:** Seed — $5M (June 2025)
- **Latest known valuation:** Not publicly disclosed
- **Total disclosed equity funding:** $7.3M
- **Stage:** seed
- **Status:** private
- **Industries:** healthtech, biotech-life-sciences
- **Coverage:** full
- **Last updated:** 2026-11-15
- **Latest funding investors:** Fortify Ventures, Inventure, Ayuh Ventures, APEX, SOSV, Afterwork Ventures, FIRSTPICK, Seaside Ventures

## Key facts

- Ayuh named in the 2024 pre-seed and 2025 seed announcements.
- The 2025 seed was co-led by Fortify Ventures and Inventure.
- Company describes Nettle's UK and EU Class IIa clearance; no US approval is implied.

## Funding history

- Seed · $5M · June 2025
  Source: https://paaomasijoittajat.fi/en/ajankohtaista/news/30188/samphire-neuroscience-raises-5-million-seed-round-to-advance-breakthrough-neurotechnology-for-womens-health/
- Pre-Seed · $2.3M · February 2024
  Source: https://firstpick.vc/blog/samphire-neuroscience-is-building-a-brain-stimulating-wearable-for-period-pain/

## Investors in our directory

- https://venturecapitaltracker.com/fund/ayuh-ventures

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** November 15, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/samphire-neuroscience
